Evidence map›Paper›PMID 19609589›Full record

ReviewEuropean archives of psychiatry and clinical neuroscience2009

Cannabis and psychosis/schizophrenia: human studies.

Deepak Cyril D'Souza, Richard Andrew Sewell, Mohini Ranganathan

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in European archives of psychiatry and clinical neuroscience, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 7 pooled it
19.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 7 syntheses or guidelines pooled it, 274 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Cannabis use and psychosis: a review of reviews.European archives of psychiatry and clinical neuroscience · 2020
    Pooled it
  5. Pooled it
  6. Cannabis and schizophrenia.The Cochrane database of systematic reviews · 2014
    Pooled it
  7. Pooled it
  8. Trial
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Subjective effects of simultaneous alcohol and cannabis versus alcohol-only use: A qualitative analysis.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2023
    Article
  16. Article
  17. A brain imaging study of dopamine receptor DFrontiers in psychiatry · 2023
    Article
  18. Review
  19. Article
  20. Review

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Deepak Cyril D'SouzaSchizophrenia Biological Research Center, Psychiatry Service, VA Connecticut Healthcare System, 116A, 950 Campbell Avenue, West Haven, CT 06516, USA. deepak.dsouza@yale.edu
Richard Andrew Sewell
Mohini Ranganathan
VA Connecticut Healthcare System · US

Funding

NEUROBIOLOGY OF CANNABIS EFFECTSR01DA012382 · NIDA · YALE UNIVERSITY · PI D'SOUZA, DEEPAK CYRIL · 2001 to 2009
$1.3M
NIDA NIH HHS R01 DA012382
6 · The paper itself

Abstract

The association between cannabis use and psychosis has long been recognized. Recent advances in knowledge about cannabinoid receptor function have renewed interest in this association. Converging lines of evidence suggest that cannabinoids can produce a full range of transient schizophrenia-like positive, negative, and cognitive symptoms in some healthy individuals. Also clear is that in individuals with an established psychotic disorder, cannabinoids can exacerbate symptoms, trigger relapse, and have negative consequences on the course of the illness. The mechanisms by which cannabinoids produce transient psychotic symptoms, while unclear may involve dopamine, GABA, and glutamate neurotransmission. However, only a very small proportion of the general population exposed to cannabinoids develop a psychotic illness. It is likely that cannabis exposure is a "component cause" that interacts with other factors to "cause" schizophrenia or a psychotic disorder, but is neither necessary nor sufficient to do so alone. Nevertheless, in the absence of known causes of schizophrenia, the role of component causes remains important and warrants further study. Dose, duration of exposure, and the age of first exposure to cannabinoids may be important factors, and genetic factors that interact with cannabinoid exposure to moderate or amplify the risk of a psychotic disorder are beginning to be elucidated. The mechanisms by which exposure to cannabinoids increase the risk for developing a psychotic disorder are unknown. However, novel hypotheses including the role of cannabinoids on neurodevelopmental processes relevant to psychotic disorders are being studied.

Indexed as

AssociationCannabisCognition DisordersHumansMarijuana AbuseNeurotransmitter AgentsPsychotic DisordersSchizophreniaNeurotransmitter Agents

Identifiers

PMID19609589
PMCPMC2864503
OpenAlexW2132835664

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.